---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000063"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-07-23T11:00:14+00:00"
generated_at: "2026-07-23T11:05:44.569331+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure Q2 net revenue $183.6M (+16% YoY); raises FY 2026 guidance

## Summary
- Net revenue $183.6M, up 16% YoY; net loss $15.7M ($0.13 loss per share).
- Adjusted EBITDA $10.8M; gross margin 78% vs 74% a year ago.
- FY 2026 revenue guidance raised to $710M-$725M (prev $690M-$710M); adjusted EBITDA guidance raised to $0M-$15M.
- CE Mark received for Optune Pax for locally advanced pancreatic cancer; 285 active patients on Optune Pax in U.S.
- Global active patients 5,128, up 11% YoY for Optune Gio; Optune Lua active patients up 51%.

## SEC filing metadata
- accession: 0001645113-26-000063
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-07-23T11:00:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/0001645113-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/nvcr-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000063
- JSON: https://secwatch.observer/filing/0001645113-26-000063.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.